Adjuvant chemotherapy or chemoimmunotherapy in the management of primary malignant melanoma of level III, IV, or V.
D000328:Adult; D000367:Age Factors; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001500:BCG Vaccine / Q000627:therapeutic use; D001428:Bacterial Vaccines / Q000627:therapeutic use; D003606:Dacarbazine / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011344:Procarbazine / Q000008:administration & dosage; D011425:Propionibacterium acnes / Q000276:immunology; D013308:Streptonigrin / Q000008:administration & dosage; D013852:Thiotepa / Q000008:administration & dosage; D014747:Vinblastine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D001500:BCG Vaccine; D001428:Bacterial Vaccines; D013308:Streptonigrin; D011344:Procarbazine; D014747:Vinblastine; D003606:Dacarbazine; D013852:Thiotepa; D008727:Methotrexate